“Gene editing and cell therapy, they’re going to be entrenched modalities, much like small molecules and antibodies are today, that will fundamentally reshape healthcare.” says Devyn Smith. Devyn Smith, CEO of Arbor Biotechnologies and Chairman of the Alliance for Regenerative
Mabion’s position as a cost-effective, high-quality CDMO in Central Europe offers an attractive option for North American biotechs looking to optimise their manufacturing strategies.
Joerg Ahlgrimm, CEO of SK pharmteco, believes the CDMO industry is heading for significant consolidation: “If you fast forward 10 years, there will probably be 10-15 large, multi-modality CDMOs, with many smaller and specialised ones being bought.” Joerg Ahlgrimm brings
OneSource Specialty Pharma, a newly established CDMO, was officially launched at CPHI Milan following the merger of three CDMO businesses within the Strides Group. The company specialises in biologics, drug-device combinations, and soft gelatin capsules, supported by over 30 years
This report summarises key supply chain events and their expected impact on life science prices over the period September-October 2024. Existing geopolitical tensions and fluctuating commodity stocks are expected to drive global market volatility and supply chain disruptions Contract Development
Bora Pharmaceuticals Co., Ltd. has announced a strategic investment in Tanvex Biopharma Co., Ltd., aimed at combining their biomanufacturing facilities to offer a global solution for biologics development and supply. The investment will result in Bora holding approximately 30.5% of
The Indian CDMO market is forecast to double over the next five years, as ‘the pharmacy of the world’ becomes increasingly attractive for contract development and manufacturing outsourcing. To understand what is behind this rapid growth, we spoke to Akhil
Chime Biologics has announced plans to significantly scale up its manufacturing operations in China and expand into the Asia-Pacific markets. The contract development and manufacturing organisation (CDMO) will increase its drug substance capacity from 28,000L to approximately 100,000L. This expansion
The high-growth India CDMO market is benefiting from this shifting geo-political tensions. We explore India’s impressive growth trajectory, which is forecast to see the CDMO market double over the next five years. Here is an overview of the market, with infographic and expert analysis.
This report summarises key macros events and their expected impact on life science prices over the period Jul-August 2024 Contract Development & Manufacturing The BIOSECURE Act, currently under consideration in the US Congress, is poised to significantly impact the biologics
